Cargando…

Benznidazole Treatment: Time- and Dose-Dependence Varies with the Trypanosoma cruzi Strain

As the development of new drugs for Chagas disease is not a priority due to its neglected disease status, an option for increasing treatment adherence is to explore alternative treatment regimens, which may decrease the incidence of side effects. Therefore, we evaluated the efficacy of different the...

Descripción completa

Detalles Bibliográficos
Autores principales: Fonseca, Kátia da Silva, Perin, Luísa, de Paiva, Nívia Carolina Nogueira, da Silva, Beatriz Cristiane, Duarte, Thays Helena Chaves, Marques, Flávia de Souza, Costa, Guilherme de Paula, Molina, Israel, Correa-Oliveira, Rodrigo, Vieira, Paula Melo de Abreu, Carneiro, Cláudia Martins
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8229751/
https://www.ncbi.nlm.nih.gov/pubmed/34207764
http://dx.doi.org/10.3390/pathogens10060729
_version_ 1783713051620409344
author Fonseca, Kátia da Silva
Perin, Luísa
de Paiva, Nívia Carolina Nogueira
da Silva, Beatriz Cristiane
Duarte, Thays Helena Chaves
Marques, Flávia de Souza
Costa, Guilherme de Paula
Molina, Israel
Correa-Oliveira, Rodrigo
Vieira, Paula Melo de Abreu
Carneiro, Cláudia Martins
author_facet Fonseca, Kátia da Silva
Perin, Luísa
de Paiva, Nívia Carolina Nogueira
da Silva, Beatriz Cristiane
Duarte, Thays Helena Chaves
Marques, Flávia de Souza
Costa, Guilherme de Paula
Molina, Israel
Correa-Oliveira, Rodrigo
Vieira, Paula Melo de Abreu
Carneiro, Cláudia Martins
author_sort Fonseca, Kátia da Silva
collection PubMed
description As the development of new drugs for Chagas disease is not a priority due to its neglected disease status, an option for increasing treatment adherence is to explore alternative treatment regimens, which may decrease the incidence of side effects. Therefore, we evaluated the efficacy of different therapeutic schemes with benznidazole (BNZ) on the acute and chronic phases of the disease, using mice infected with strains that have different BNZ susceptibilities. Our results show that the groups of animals infected by VL-10 strain, when treated in the chronic phase with a lower dose of BNZ for a longer period of time (40 mg/kg/day for 40 days) presented better treatment efficacy than with the standard protocol (100 mg/kg/day for 20 days) although the best result in the treatment of the animals infected by the VL-10 strain was with100 mg/kg/day for 40 days. In the acute infection by the Y and VL-10 strains of T. cruzi, the treatment with a standard dose, but with a longer time of treatment (100 mg/kg/day for 40 days) presented the best results. Given these data, our results indicate that for BNZ, the theory of dose and time proportionality does not apply to the phases of infection.
format Online
Article
Text
id pubmed-8229751
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-82297512021-06-26 Benznidazole Treatment: Time- and Dose-Dependence Varies with the Trypanosoma cruzi Strain Fonseca, Kátia da Silva Perin, Luísa de Paiva, Nívia Carolina Nogueira da Silva, Beatriz Cristiane Duarte, Thays Helena Chaves Marques, Flávia de Souza Costa, Guilherme de Paula Molina, Israel Correa-Oliveira, Rodrigo Vieira, Paula Melo de Abreu Carneiro, Cláudia Martins Pathogens Article As the development of new drugs for Chagas disease is not a priority due to its neglected disease status, an option for increasing treatment adherence is to explore alternative treatment regimens, which may decrease the incidence of side effects. Therefore, we evaluated the efficacy of different therapeutic schemes with benznidazole (BNZ) on the acute and chronic phases of the disease, using mice infected with strains that have different BNZ susceptibilities. Our results show that the groups of animals infected by VL-10 strain, when treated in the chronic phase with a lower dose of BNZ for a longer period of time (40 mg/kg/day for 40 days) presented better treatment efficacy than with the standard protocol (100 mg/kg/day for 20 days) although the best result in the treatment of the animals infected by the VL-10 strain was with100 mg/kg/day for 40 days. In the acute infection by the Y and VL-10 strains of T. cruzi, the treatment with a standard dose, but with a longer time of treatment (100 mg/kg/day for 40 days) presented the best results. Given these data, our results indicate that for BNZ, the theory of dose and time proportionality does not apply to the phases of infection. MDPI 2021-06-09 /pmc/articles/PMC8229751/ /pubmed/34207764 http://dx.doi.org/10.3390/pathogens10060729 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Fonseca, Kátia da Silva
Perin, Luísa
de Paiva, Nívia Carolina Nogueira
da Silva, Beatriz Cristiane
Duarte, Thays Helena Chaves
Marques, Flávia de Souza
Costa, Guilherme de Paula
Molina, Israel
Correa-Oliveira, Rodrigo
Vieira, Paula Melo de Abreu
Carneiro, Cláudia Martins
Benznidazole Treatment: Time- and Dose-Dependence Varies with the Trypanosoma cruzi Strain
title Benznidazole Treatment: Time- and Dose-Dependence Varies with the Trypanosoma cruzi Strain
title_full Benznidazole Treatment: Time- and Dose-Dependence Varies with the Trypanosoma cruzi Strain
title_fullStr Benznidazole Treatment: Time- and Dose-Dependence Varies with the Trypanosoma cruzi Strain
title_full_unstemmed Benznidazole Treatment: Time- and Dose-Dependence Varies with the Trypanosoma cruzi Strain
title_short Benznidazole Treatment: Time- and Dose-Dependence Varies with the Trypanosoma cruzi Strain
title_sort benznidazole treatment: time- and dose-dependence varies with the trypanosoma cruzi strain
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8229751/
https://www.ncbi.nlm.nih.gov/pubmed/34207764
http://dx.doi.org/10.3390/pathogens10060729
work_keys_str_mv AT fonsecakatiadasilva benznidazoletreatmenttimeanddosedependencevarieswiththetrypanosomacruzistrain
AT perinluisa benznidazoletreatmenttimeanddosedependencevarieswiththetrypanosomacruzistrain
AT depaivaniviacarolinanogueira benznidazoletreatmenttimeanddosedependencevarieswiththetrypanosomacruzistrain
AT dasilvabeatrizcristiane benznidazoletreatmenttimeanddosedependencevarieswiththetrypanosomacruzistrain
AT duartethayshelenachaves benznidazoletreatmenttimeanddosedependencevarieswiththetrypanosomacruzistrain
AT marquesflaviadesouza benznidazoletreatmenttimeanddosedependencevarieswiththetrypanosomacruzistrain
AT costaguilhermedepaula benznidazoletreatmenttimeanddosedependencevarieswiththetrypanosomacruzistrain
AT molinaisrael benznidazoletreatmenttimeanddosedependencevarieswiththetrypanosomacruzistrain
AT correaoliveirarodrigo benznidazoletreatmenttimeanddosedependencevarieswiththetrypanosomacruzistrain
AT vieirapaulamelodeabreu benznidazoletreatmenttimeanddosedependencevarieswiththetrypanosomacruzistrain
AT carneiroclaudiamartins benznidazoletreatmenttimeanddosedependencevarieswiththetrypanosomacruzistrain